Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
BEL-X-HG in Advanced Refractory Solid Malignancies
NCT03256331Phase 1Terminated
- Sponsor
- BELX Bio-Pharmaceutical Co. Ltd.
- Start
- Jun 2017
- Primary completion
- Mar 2020
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 1, open-label, single-arm trial of BEL-X-HG in solid tumor (advanced stage), sponsored by BELX Bio-Pharmaceutical Co. Ltd. Primary endpoint: Maximum Tolerated Dose at 28 days. Started Jun 2017; status: terminated.
02
Drugs
BEL-X-HG
03
Conditions
solid tumor (advanced stage)
Beyond the preview
Go deeper on NCT03256331.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT03256331.